Trial · NCT01825200
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Common Hypersensitivity Reactions as Measure of Safety | Flublok | 31 | participants | ||
| Number of Participants With Common Hypersensitivity Reactions as Measure of Safety | Afluria | 21 | participants | ||
| Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration | Flublok | Serious Adverse Events (SAEs) | 5 | participants | |
| Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration | Afluria | Serious Adverse Events (SAEs) | 10 | participants | |
| Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration | Flublok | Medically-Attended Unsolicited Adverse Events | 53 | participants | |
| Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration | Afluria | Medically-Attended Unsolicited Adverse Events | 51 | participants | |
| Number of Participants With Local and Systemic Events Reported as a Measure of Safety | Flublok | 432 | participants | ||
| Number of Participants With Local and Systemic Events Reported as a Measure of Safety | Afluria | 480 | participants | ||
| Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety | Flublok | Day 0 | 5 | participants | |
| Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety | Afluria | Day 0 | 3 | participants | |
| Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety | Flublok | Days 0-7 | 25 | participants | |
| Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety | Afluria | Days 0-7 | 12 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01825200/results